• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » WuXi PharmaTech goes private

WuXi PharmaTech goes private

August 17, 2015
CenterWatch Staff

WuXi PharmaTech has entered into a merger agreement with New WuXi Life Science and WuXi Merger, a wholly owned subsidiary of Parent.

Parent will acquire the company for cash consideration equal to $5.75 per ordinary share of the company and $46 per American Depositary Share (ADS) of the company, each representing eight shares, or about $3.3 billion in aggregate cash consideration. That figure represents a 16.5% premium over the closing price of $39.50 per ADS as quoted by the New York Stock Exchange on April 29, and a premium of 18.9% and 20.1%, respectively, over the company’s 30- and 60- trading day volume-weighted average price as quoted by the NYSE prior to April 29, 2015, the last trading day prior to the company’s announcement on April 30 that it had received a non-binding “going private” proposal.

Immediately following the consummation of the transactions contemplated by the merger agreement, Parent will be beneficially owned by a consortium comprised of:

  • New investors including affiliates of or funds managed or advised by Ally Bridge Group Capital Partners, Boyu Capital, Temasek Life Sciences Private and Ping An Insurance;
  • Hillhouse Fund II, an existing shareholder of the company and an affiliate of Hillhouse Capital; and
  • Founders and executive officers of the company who have elected to roll-over their interest in the company in connection with the merger including Dr. Ge Li, the chairman and chief executive officer; Xiaozhong Liu, an executive vice president and a director; Zhaohui Zhang, a senior vice president of operations, the head of domestic marketing and a director; and Dr. Ning Zhao, a senior vice president of operations, the head of corporate human resources and a director.

The merger, which is expected to close during the fourth quarter of 2015, is subject to shareholder approval as well as certain other customary closing conditions.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing